Cyathus Exquirere Pharmaforschungsgmbh

Executive Summary

Cyathus Exquirere Pharmaforschungsgmbh is a privately held Austrian pharmaceutical company that has transitioned from a contract R&D organization to a commercial entity specializing in the marketing, distribution, and global licensing of innovative generic drug formulations. Founded in 2018 and headquartered in Vienna, the company leverages advanced drug delivery technologies to develop patient-friendly versions of established pharmaceutical substances. By focusing on differentiated generics, Cyathus aims to address unmet needs in drug administration, such as improved bioavailability, extended release, or enhanced patient compliance. Its business model involves in-licensing or co-developing products and then out-licensing them to partners for commercialization, reducing capital expenditure and risk.

Upcoming Catalysts (preview)

• Q4 2026First proprietary product regulatory filing in EU30% success
• H2 2026Partnership or licensing deal for key technology platform40% success
• Q3 2026Completion of pivotal bioequivalence study for lead candidate25% success